Professor David Allsup D.J.Allsup@hull.ac.uk
Professor of Haematology
CLL Research
People Involved
Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors (2025)
Journal Article
Molica, S., & Allsup, D. (2025). Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors. Cancers, 17(1), Article 119. https://doi.org/10.3390/cancers17010119Chronic lymphocytic leukemia (CLL) treatment has evolved from traditional chemotherapy to targeted therapies, such as Bruton tyrosine kinase (BTK) and BCL-2 inhibitors with significant improvements in survival rates and a transformation of CLL into a... Read More about Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors.
Prevalence of BTK and PLCG2 Mutations in CLL Patients With Disease Progression on BTK Inhibitor Therapy: A Meta‐Analysis (2024)
Journal Article
Molica, S., Allsup, D., & Giannarelli, D. (online). Prevalence of BTK and PLCG2 Mutations in CLL Patients With Disease Progression on BTK Inhibitor Therapy: A Meta‐Analysis. American Journal of Hematology, https://doi.org/10.1002/ajh.27544
High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition (2024)
Journal Article
James, D., Green, S., Molica, S., & Allsup, D. (2024). High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition. Case Reports in Hematology, 2024, Article 1813512. https://doi.org/10.1155/2024/1813512The coexistence of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) in the same patient is exceedingly rare, with only a few cases reported in the literature. Here, we report a patient with CML who, having achieved a major molecu... Read More about High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition.
Prevalence of BTK and PLCG2 Mutations in BTK Inhibitor Treated CLL Patients Who Experience Disease Progression: A Meta-Analysis (2024)
Presentation / Conference Contribution
Molica, S., Allsup, D., & Giannarelli, D. (2024, December). Prevalence of BTK and PLCG2 Mutations in BTK Inhibitor Treated CLL Patients Who Experience Disease Progression: A Meta-Analysis. Presented at American Society of Haematology, San Diego
Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia (2024)
Journal Article
Molica, S., Allsup, D., & Giannarelli, D. (online). Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia. American Journal of Hematology, https://doi.org/10.1002/ajh.27437The emergence of Bruton's tyrosine kinase (BTK) inhibitors marked a significant advancement in chronic lymphocytic leukemia (CLL) management, especially for high-risk patients. 1 Ibrutinib, the pioneering BTK inhibitor, has undergone extensive study.... Read More about Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia.